Atara Biotherapeutics reported a net loss of $74.8 million for Q1 2023, with cash, cash equivalents, and short-term investments totaling $205.4 million. The company believes its current cash resources will fund planned operations into Q2 2024. Discussions with the FDA regarding tab-cel are progressing, and the first patients in Europe have been treated with EBVALLO following the transfer of EC Marketing Authorization to Pierre Fabre.